🔍

SANOFICONR - Sanofi Consumer

📊 NSE: SANOFICONR 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/14/2025 12:48

📢 Recent Corporate Announcements

Sanofi Consumer Healthcare Designates Nupur Gurbaxani and Viral Shah as Senior Management

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 25 Feb 2026, 08:57 PM

Sanofi Consumer Healthcare India Limited has elevated two key directors, Ms. Nupur Gurbaxani and Mr. Viral Shah, to Senior Management Personnel (SMP) status effective February 25, 2026. Ms. Gurbaxani, Director of Brand & Innovation, brings 18 years of experience from firms like Novartis and Abbott to lead brand transformation. Mr. Shah, Director of External Manufacturing, has 20 years of industry experience and is tasked with strengthening 'Make in India' initiatives and export growth. These designations signal a focus on strengthening the leadership team to drive digital-first marketing and manufacturing infrastructure.

Ms. Nupur Gurbaxani (Director, Brand & Innovation) designated as SMP with 18+ years of industry experience.
Mr. Viral Shah (Director, External Manufacturing) designated as SMP with 20+ years of experience in manufacturing and exports.
Designations are effective from February 25, 2026, following Board and NRC recommendations.
Strategic focus placed on 'Make in India' infrastructure and digital-first brand penetration turnaround.

💡 Investors should view this as a routine governance update strengthening the leadership tier. Monitor the company's upcoming quarterly results for improvements in brand penetration and manufacturing efficiencies attributed to these leaders.

Sanofi Consumer Healthcare Designates Two Directors as Senior Management Personnel

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 25 Feb 2026, 08:53 PM

Sanofi Consumer Healthcare India Limited has designated Ms. Nupur Gurbaxani and Mr. Viral Shah as Senior Management Personnel effective February 25, 2026. Ms. Gurbaxani, Director of Brand & Innovation, brings over 18 years of experience from firms like Novartis and Abbott to drive brand penetration. Mr. Shah, Director of External Manufacturing, has over 20 years of experience and focuses on "Make in India" initiatives and export growth. These designations formalize the leadership roles of key executives who joined the company in mid-2024.

Ms. Nupur Gurbaxani (18+ years experience) designated as Senior Management Personnel
Mr. Viral Shah (20+ years experience) designated as Senior Management Personnel
Designations are effective from February 25, 2026, following a Board meeting
Leadership focus remains on brand transformation, digital-first strategy, and manufacturing infrastructure

💡 No immediate action is required as these are internal designations of existing directors. Monitor the impact of their leadership on brand growth and manufacturing efficiency in future earnings reports.

Sanofi Consumer Healthcare Q4 Profit Jumps 50% to ₹665 MN; ₹75 Dividend Declared

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 25 Feb 2026, 08:30 PM

Sanofi Consumer Healthcare India (SCHIL) reported a robust Q4 performance with revenue growing 47% YoY to ₹2,510 million and net profit surging 50% to ₹665 million. For the full year 2025, the company achieved a 21% revenue growth and a 33% increase in PAT, reaching ₹2,401 million. The board has recommended a substantial dividend of ₹75 per share, reflecting strong cash generation. Growth was primarily driven by a 23% rise in domestic sales and the successful relaunch of recalled products.

Q4 Revenue grew 47% YoY to ₹2,510 million, while Net Profit rose 50% to ₹665 million.
Full-year FY25 PAT increased by 33% to ₹2,401 million on total revenue of ₹8,784 million.
Declared a significant dividend of ₹75 per share for the financial year ended December 31, 2025.
Domestic sales grew by 23% in Q4, supported by brand relaunches and core portfolio strength.
Export sales for Q4 grew 9.3x and full-year exports grew 158%, albeit from a low base.

💡 The strong double-digit growth and high dividend payout indicate successful post-demerger stabilization and operational efficiency. Investors may consider this a positive signal for long-term value in the consumer healthcare space, given the strength of brands like Combiflam and Allegra.

Sanofi Consumer Healthcare FY25 Net Profit Jumps 33% to ₹240 Cr; Recommends ₹75 Dividend

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 25 Feb 2026, 07:57 PM

Sanofi Consumer Healthcare India reported a strong financial performance for the year ended December 31, 2025, with annual revenue growing 21% to ₹8,784 million. Net profit for the full year surged by 32.6% to ₹2,401 million, driven by robust operational performance and higher other income. The Board has recommended a substantial final dividend of ₹75 per equity share, highlighting strong cash flow generation. Quarterly growth was even more pronounced, with Q4 revenue increasing 47% year-on-year to ₹2,510 million.

Full-year FY25 revenue increased 21.2% to ₹8,784 million from ₹7,245 million in FY24.
Net profit for FY25 rose to ₹2,401 million, up from ₹1,810 million in the previous year.
Board recommended a final dividend of ₹75 per equity share (750% of face value).
Earnings Per Share (EPS) for FY25 improved significantly to ₹104.27 from ₹78.59.
Q4 FY25 net profit stood at ₹665 million, a 50% increase compared to ₹443 million in Q4 FY24.

💡 Investors should view these results positively given the strong double-digit growth in both top-line and bottom-line, coupled with a high dividend payout. The stock remains attractive for those seeking a combination of growth in the consumer healthcare space and high yield.

Sanofi Consumer Healthcare Recommends Rs 75 Dividend; FY25 Net Profit Rises 33%

🟢 POSITIVE ⭐ 8/10

DIVIDEND 📅 25 Feb 2026, 07:37 PM

Sanofi Consumer Healthcare India has recommended a final dividend of Rs. 75 per share for the financial year ended December 31, 2025. The company reported a strong financial performance with annual revenue growing 21% to Rs. 8,784 million. Net profit for the full year increased significantly by 33% to Rs. 2,401 million compared to the previous year. The quarterly performance was also robust, with Q4 profit rising to Rs. 665 million from Rs. 443 million year-on-year.

Recommended a final dividend of Rs. 75 per equity share of face value Rs. 10.
Annual Revenue from Operations grew 21.2% YoY to Rs. 8,784 million in FY25.
Net Profit for the full year surged 32.7% to Rs. 2,401 million from Rs. 1,810 million.
Earnings Per Share (EPS) increased to Rs. 104.27 from Rs. 78.59 in the previous year.
Q4 FY25 revenue stood at Rs. 2,510 million, a 47% increase over Q4 FY24.

💡 Investors should note the strong growth trajectory and the substantial dividend payout which reflects robust cash flows. The stock is likely to be viewed favorably by both growth and income-seeking investors due to the earnings outperformance.

Sanofi Consumer Healthcare FY25 Net Profit Jumps 33% to ₹2,401 Mn; ₹75/Share Dividend Declared

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 25 Feb 2026, 07:11 PM

Sanofi Consumer Healthcare India reported a strong performance for the financial year ended December 31, 2025, with annual revenue growing 21% to ₹8,784 million. Net profit for the full year increased significantly by 32.6% to ₹2,401 million, supported by improved operational efficiencies. The Board has recommended a substantial final dividend of ₹75 per share, reflecting a high payout ratio and strong cash position. Quarterly performance was also robust, with Q4 revenue up 47% year-on-year to ₹2,510 million.

Full-year FY25 Revenue from Operations rose 21.2% YoY to ₹8,784 million versus ₹7,245 million.
Net Profit for FY25 increased to ₹2,401 million from ₹1,810 million in the previous year.
Recommended a final dividend of ₹75 per equity share of face value ₹10 for the financial year.
Q4 FY25 Net Profit grew 50% YoY to ₹665 million compared to ₹443 million in Q4 FY24.
Earnings Per Share (EPS) improved significantly to ₹104.27 for FY25 from ₹78.59 in FY24.

💡 Investors should react positively to the strong double-digit growth in both revenue and profitability alongside a very generous dividend payout. The company's transition and focus on consumer healthcare appear to be yielding high margins and robust cash flows.

Sanofi Consumer Healthcare Submits Q3 FY26 SEBI Reg 74(5) Compliance Certificate

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 13 Jan 2026, 03:58 PM

Sanofi Consumer Healthcare India Limited has filed its quarterly compliance certificate for the period ending December 31, 2025. The document, provided by registrar MUFG Intime India Private Limited, confirms that all dematerialization requests were handled according to SEBI regulations. It ensures that share certificates received were cancelled and the register of members was updated within the mandated timelines. This filing is a standard administrative requirement for listed entities in India.

Compliance certificate for the quarter ended December 31, 2025, submitted to BSE and NSE.
Registrar MUFG Intime India confirmed processing of dematerialization requests.
Securities comprised in certificates are listed on relevant stock exchanges.
Confirms cancellation of physical certificates and update of member registers.

💡 This is a routine administrative filing with no impact on company fundamentals; no action is necessary for shareholders.

Sanofi Consumer Healthcare India to Close Trading Window from Jan 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 06:25 PM

Sanofi Consumer Healthcare India Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI insider trading regulations. This closure is preparatory to the declaration of the company's audited standalone financial results for the fiscal year ending December 31, 2025. The trading restriction will remain in effect until 48 hours after the financial results are officially communicated to the stock exchanges. This is a standard regulatory procedure for all listed entities in India.

Trading window closure effective from January 1, 2026
Closure is for the purpose of declaring Audited Standalone Financial Results for the year ended December 31, 2025
Window to reopen 48 hours after the announcement of results to BSE and NSE
Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015

💡 This is a routine regulatory filing with no impact on company fundamentals; investors should focus on the upcoming financial results for performance assessment.

View All SANOFICONR Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single business segment, 'Pharmaceutical Business'. For Q3 2025, revenue was INR 233.9 Cr, representing a 46% YoY growth. For the nine months ended September 2025, revenue reached INR 627.4 Cr, up 13% YoY.

Geographic Revenue Split

In Q3 2025, Domestic sales grew by 20% YoY, while Export sales grew by 1031% YoY on a low base. For the nine-month period, Domestic sales grew by 1% and Export sales grew by 96% YoY.

Profitability Margins

For CY 2024, the Operating Profit Margin was 35% (down from 39% in 2023) and the Net Profit Margin was 25% (down from 30% in 2023). Q3 2025 Net Profit was INR 62.9 Cr, a 40% increase YoY.

EBITDA Margin

In CY 2024, the company achieved an EBITDA of INR 255.2 Cr with an EBITDA margin of 35%. Core profitability remains strong despite a slight margin compression compared to the restated 2023 figures.

Credit Rating & Borrowing

Not disclosed in available documents; however, the company reported a Debt-Equity ratio of 'NA', indicating a debt-free balance sheet.

⚙️ Operational Drivers

Operational analysis data not yet available for this company.

📈 Strategic Growth

Expected Growth Rate

13%

Growth Strategy

Growth is driven by the 'India for India' strategy, leveraging global Opella expertise to implement local Consumer Healthcare (CHC) strategies. Key drivers include the successful re-establishment of voluntarily recalled products and active engagement with regulators to shape OTC regulations in India. The transition to a standalone entity under CD&R ownership (50% stake) aims to enhance local agility and decision-making.

Products & Services

Consumer healthcare and pharmaceutical products (OTC medicines).

New Products/Services

The company focused on re-establishing voluntarily recalled products within the year, which have successfully regained market presence.

Market Expansion

Focus on the Indian domestic market, which saw 20% growth in Q3 2025, and expanding export reach from a low base.

Strategic Alliances

The company demerged from Sanofi India Limited in June 2024. Globally, Sanofi sold a 50% controlling stake in the parent Opella group to Clayton, Dubilier & Rice (CD&R) in April 2025.

🌍 External Factors

Industry Trends

The Indian consumer healthcare sector is shifting toward standalone specialized entities. Regulatory evolution in OTC frameworks is a key trend, with the company actively participating in shaping these norms to increase self-care accessibility and market reach.

Competitive Moat

The moat is derived from global science-based self-care expertise via the Opella group and a resilient brand portfolio that successfully recovered from product recalls. The 'India for India' strategy provides local agility while maintaining global quality standards.

Consumer Behavior

Increasing consumer demand for simpler, more accessible, and more effective self-care solutions.

⚖️ Regulatory & Governance

Industry Regulations

The company is actively engaged with regulatory authorities to help shape Over-the-Counter (OTC) regulations in India, which is critical for its standalone consumer healthcare strategy.

Legal Contingencies

No material fines, penalties, or settlement amounts were paid to regulators or law enforcement agencies in CY 2024.

⚠️ Risk Analysis

Key Uncertainties

Key risks include regulatory shifts in OTC drug classifications and potential product quality issues or recalls, which can disrupt market presence for up to a year.